Abstract: A seawater mineral extract derived from seawater having a salinity of from 3.4% Brix to 3.6% Brix, wherein the seawater mineral extract comprises a mineral salt content of at least 20% of the overall seawater extract.

Abstract: The present invention discloses a spray drying process characterized by continuous preparation and immediate spray drying of a solution comprising at least one active pharmaceutical ingredient and/or at least one excipient, and at least one solvent. The said active pharmaceutical ingredient(s) and solvent(s) are combined, alone or along with one or more excipients to form a first suspension. Said suspension is continuously fed to an intensifier pump that pushes said suspension through at least one micro-reaction chamber and/or at least one micro-channel where the suspension's solid(s) component(s) is(are) dissolved into said solvent(s) by means of high energy mixing I forced contact at micro, nano and molecular level to form a solution stream. The said solution stream is then immediately and continuously fed to the spray dryer through at least one atomization nozzle, drying said atomized stream to obtain solid particles and collecting said solid particles.

Abstract: An implant for ovarian decline is provided. The implant includes at least an engineered ovarian support cell an extracellular matrix substrate, and a delivery apparatus. In some embodiments, the at least an engineered ovarian support cell includes an engineered granulosa cell. In other embodiments, the at least an engineered ovarian support cell includes an engineered lutein cell. In other embodiments, the at least an engineered ovarian support cell includes an engineered theca cell.

Abstract: Expanded, nanofiber structures comprising electrospun nanofibers, a plurality of holes, and, optionally, cells are provided. Methods of making the nanofiber structures as well as methods of use thereof, particularly for wound healing, are also provided.

Abstract: The present disclosure provides a sustained formulation for prevention or treatment of autoimmune disease, comprising microparticles comprising naltrexone or pharmaceutically acceptable salts thereof, and biodegradable polymers, and a method using the same. Accordingly, it may be used to prevent or treat autoimmune diseases for a prolonged period of time with a single administration.

Abstract: A cartilage mimetic gel includes double network hydrogels. The double network hydrogels comprise a first crosslinked network and a second crosslinked network. The first crosslinked network can be formed from poly(2-acrylamido-2-methylpropane sulfonic acid). The second crosslinked network can be formed from poly(N-isopropyl acrylamide-co-acrylamide).

Abstract: Covalently linked linear polyethylenimine (PEI) clusters are provided that change conformation depending upon changes in counterion concentrations. The structures may be used for the storage, delivery, and/or transport of substances.

Abstract: Described herein are hydrogels attached to a base with the strength and fatigue comparable to that of cartilage on bone and methods of forming them. The methods and apparatuses described herein may achieve an attachment strength between a hydrogel and a substrate equivalent to the osteochondral junction. In some examples the hydrogel may be a triple-network hydrogel (such as BC-PVA-PAMPS) that is attached to a porous substrate (e.g., a titanium base) with the shear strength and fatigue strength equivalent to that of the osteochondral junction.

Abstract: An injectable medical composition includes an acrylate and a solvent. The composition has a first viscosity at temperatures below body temperature and a second viscosity at body temperature. The first viscosity is lower than the second viscosity.

Abstract: A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

Abstract: Provided is a manufacturing method of particles coated with coatable microparticles. The method is a manufacturing method of particles coated with coatable microparticles, comprising the step of adding the coatable microparticles to an inner core comprising a component of interest and a macromolecule, and, while rolling the mixture, coating the mixture while spraying a solvent that can dissolve the macromolecule, wherein the particles coated with the coatable microparticles are coated, component of interest-containing hollow particles.

Abstract: Disclosed is a controllable method for preparing phospholipid micelles, including: S1, preparing small phospholipid vesicles; S2, preparing a graphene thin-layer electrode substrate, S3, incubating, and S4, electroforming phospholipid micelles. According to the present application, lamellar graphene is used as the electrode substrate according to the present application, where a phospholipid bilayer film is firstly spread on the surface of the substrate, and phospholipid micelles are controlled in terms of formation as well as formation state by a certain alternating current electric field on the surface of graphene; the developed method of the present application is unique in design, simple in operation, and has the advantages of fast formation, short preparation cycle and good controllability.

Abstract: The invention provides a thermosensitive peptide hydrogel, which comprises water, a polyether/polyol polymer and a peptide molecule. The peptide molecule has a structure represented by the following chemical formula (1).

Abstract: Provided is a chitosan hydrogel composition including chitosan, glycerol, and a phosphate group, wherein the chitosan is crosslinked via the glycerol, the phosphate group, or a combination thereof. The temperature at which the chitosan hydrogel composition may be induced from a liquid state into a gel state may be controlled according to the content ratio of the phosphate group and the glycerol, and since printing properties and strength are affected by the gelatin concentration, the composition may be used as an ink for 3D printing.

Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Abstract: A cell or tissue embedding device having an aqueous gel serving as an immunoisolation layer, the aqueous gel containing, as components thereof, a denatured polyvinyl alcohol resin having an activated carbonyl group and a crosslinking agent is highly capable of supplying a physiologically active substance.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Abstract: Microneedle arrays and methods of forming the same can include one or more bioactive components bonded to a biocompatible material such that the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.